Generic Name and Formulations:
Mexiletine HCl 150mg, 200mg, 250mg; caps.
Various generic manufacturers
Indications for Mexiletine:
Documented life-threatening ventricular arrhythmias.
Take with food or antacid. Initially 200mg every 8hrs. Adjust dose if needed at not less than 2–3 day intervals in 50–100mg increments. Usual dose: 200–300mg every 8hrs; max 1.2g/day. If arrhythmia is controlled by ≤300mg every 8hrs, may try dividing same daily dose every 12hrs; max 450mg every 12hrs. See literature for information on rapid induction and changing from other antiarrhythmics.
Cardiogenic shock. 2nd- or 3rd- degree AV block unless paced.
Hepatic impairment. Severe heart failure. Sinus node dysfunction or intraventricular conduction defects. Hypotension. Epilepsy. Monitor ECG, blood and liver function. Pregnancy (Cat.C). Nursing mothers: not recommended.
May potentiate other antiarrhythmics, theophylline. Monitor control if used with hepatic enzyme-inducing drugs. Avoid drugs or diets that alter urinary pH.
Class IB antiarrhythmic.
GI upset, dizziness, tremor, nervousness, ataxia, chest pain, blurred vision, exacerbated arrhythmias, hepatotoxicity.
Formerly known under the brand name Mexitil.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
- Anticancer Properties of The Probiotic Kefir: A Review
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Daily Aspirin Reduced Risk of HBV-Related Hepatocellular Carcinoma
- Lanreotide Effectively Controls Diarrhea, Flushing in Neuroendocrine Tumors
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|